サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1631555

発作性夜間ヘモグロビン尿症治療の世界市場：市場規模・シェア・動向分析 (治療法別・地域別・セグメント別、2025年～2030年)

Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size, Share & Trends Analysis Report By Treatment (Medication, Stem Cell Transplant, Blood Transfusion), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
発作性夜間ヘモグロビン尿症治療の世界市場：市場規模・シェア・動向分析 (治療法別・地域別・セグメント別、2025年～2030年)
出版日: 2024年12月18日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

発作性夜間ヘモグロビン尿症治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、発作性夜間ヘモグロビン尿症 (PNH) 治療の世界市場規模は、2025年から2030年にかけてCAGR 9.6%を記録し、2030年までに99億6,000万米ドルに達すると予測されています。

血液・骨髄関連疾患の増加、高齢者人口の増加、新規治療薬の幅広い採用、生物学的製剤の出現など、いくつかの要因が市場を牽引しています。

発作性夜間ヘモグロビン尿症 (PNH) は、後天性の慢性血液疾患です。北米と欧州で約8,000～10,000例の症例が報告されている超希少疾患です。生命を脅かすこの疾患は、しばしば血栓症、持続性血管内溶血、汎血球減少の3つの病態を示します。有病率に関する情報は乏しいですが、PNHは世界中で2万人以上が罹患していると推定され、年間発症率は100万人あたり約1.3人、有病率は100万人あたり約16人です。PNHは男女に関係なく発症します。身体症状はどの年齢でも起こり得ますが、通常は30～40歳の間に発症します。

モノクローナル抗体、組換え蛋白質、環状ペプチドを含む新しい治療法が新興国市場で浸透しつつあります。しかし、ソリリスやその他の新薬候補による治療には高額な費用がかかるため、開発途上地域での採用には障壁があります。輸血と支持療法は、副作用と有効性が最適でないため、予測期間中に勢いを失うと予想されます。

発作性夜間ヘモグロビン尿症治療市場：分析概要

  • 米国では推定5,000～6,000人がPNHに罹患しており、年間約450件の新規症例が報告されています。
  • 米国では治療費が高いこと、さまざまなパイプライン医薬品が承認される可能性があること、新規治療薬が採用されていることなどから、2024年の世界のPNH治療市場は米国が大きな収益シェアを占めました。
  • 薬物による治療は、2024年に85.3%以上のシェアでPNH市場を独占しました。薬剤以外では、幹細胞移植の分野が予測期間を通じて2桁成長を遂げると予測されています。
  • 現在、16の製品がPNH治療薬として臨床評価中であり、さまざまな開発段階にあります。ALXN1210、Coversin、APL2、RA101495のような有望なパイプライン候補は、薬事承認後の商業的可能性が大きいです。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 発作性夜間ヘモグロビン尿症治療市場：変動要因・傾向・範囲

  • 市場連関の見通し
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因の分析
  • ビジネス環境分析
    • 業界分析：ポーターのファイブフォース分析
    • PESTEL分析

第4章 発作性夜間ヘモグロビン尿症治療市場：治療法別のビジネス分析

  • 市場シェア：治療法別 (2024年・2030年)
  • 治療法別ダッシュボード
  • 市場規模の予測と動向分析：治療法別 (2018～2030年)
  • 投薬
  • 幹細胞移植
  • 輸血
  • その他の治療の種類

第5章 発作性夜間ヘモグロビン尿症治療市場：地域別の推定・動向分析

  • 市場シェア：地域別 (2024年・2030年)
  • 市場ダッシュボード：地域別
  • 市場規模の予測と動向分析 (2018～2030年)
  • 北米
    • 国別 (2018～2030年)
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 国別 (2018～2030年)
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • デンマーク
    • スウェーデン
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • 国別 (2018～2030年)
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 国別 (2018～2030年)
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第6章 競合情勢

  • 参入企業概要
  • 企業の市場ポジション分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • Alexion Pharmaceuticals, Inc.
    • Apellis Pharmaceuticals
    • Novartis AG
    • F. Hoffmann-La Roche Ltd
    • Genentech, Inc.
    • BioCryst Pharmaceuticals, Inc.
    • Regeneron Pharmaceuticals Inc.
    • Sanofi
    • Pfizer Inc.
    • Amgen Inc.
図表

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global paroxysmal nocturnal hemoglobinuria treatment market, by region, 2018 - 2030 (USD Billion)
  • Table 4. Global paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 5. North America paroxysmal nocturnal hemoglobinuria treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 6. North America paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 7. U.S. paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 8. Canada paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 9. Mexico paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 10. Europe paroxysmal nocturnal hemoglobinuria treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 11. Europe paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 12. UK paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 13. Germany paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 14. France paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 15. Italy paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 16. Spain paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 17. Norway paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 18. Denmark paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 19. Sweden paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 20. Asia Pacific paroxysmal nocturnal hemoglobinuria treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 21. Asia Pacific paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 22. Japan paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 23. China paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018-2030 (USD Billion)
  • Table 24. India paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 25. Australia paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 26. South Korea paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 27. Thailand paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 28. Latin America paroxysmal nocturnal hemoglobinuria treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 29. Latin America paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 30. Brazil paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 31. Argentina paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 32. Middle East & Africa paroxysmal nocturnal hemoglobinuria treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 33. Middle East & Africa paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 34. South Africa paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 35. Saudi Arabia paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 36. UAE paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 37. Kuwait paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Paroxysmal Nocturnal Hemoglobinuria Treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Treatment outlook (USD Billion)
  • Fig. 10 Competitive landscape
  • Fig. 11 Paroxysmal Nocturnal Hemoglobinuria Treatment market dynamics
  • Fig. 12 Paroxysmal Nocturnal Hemoglobinuria Treatment market: Porter's five forces analysis
  • Fig. 13 Paroxysmal Nocturnal Hemoglobinuria Treatment market: PESTLE analysis
  • Fig. 14 Paroxysmal Nocturnal Hemoglobinuria Treatment market: Treatment segment dashboard
  • Fig. 15 Paroxysmal Nocturnal Hemoglobinuria Treatment market: Treatment market share analysis, 2024 & 2030
  • Fig. 16 Medication market, 2018 - 2030 (USD Billion)
  • Fig. 17 Stem cell transplant market, 2018 - 2030 (USD Billion)
  • Fig. 18 Blood transfusion market, 2018 - 2030 (USD Billion)
  • Fig. 19 Other treatment types market, 2018 - 2030 (USD Billion)
  • Fig. 20 Paroxysmal Nocturnal Hemoglobinuria Treatment market revenue, by region
  • Fig. 21 Regional marketplace: Key takeaways
  • Fig. 22 North America paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 23 U.S. country dynamics
  • Fig. 24 U.S. paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 25 Canada country dynamics
  • Fig. 26 Canada paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 27 Mexico country dynamics
  • Fig. 28 Mexico paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 29 Europe paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 30 UK country dynamics
  • Fig. 31 UK paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 32 Germany country dynamics
  • Fig. 33 Germany paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 34 France country dynamics
  • Fig. 35 France paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 36 Italy country dynamics
  • Fig. 37 Italy paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 38 Spain country dynamics
  • Fig. 39 Spain paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 40 Norway country dynamics
  • Fig. 41 Norway paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 42 Sweden country dynamics
  • Fig. 43 Sweden paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 44 Denmark country dynamics
  • Fig. 45 Denmark paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 46 Asia Pacific paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 47 Japan country dynamics
  • Fig. 48 Japan paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 49 China country dynamics
  • Fig. 50 China paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 51 India country dynamics
  • Fig. 52 India paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 53 Australia country dynamics
  • Fig. 54 Australia paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 55 South Korea country dynamics
  • Fig. 56 South Korea paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 57 Thailand country dynamics
  • Fig. 58 Thailand paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 59 Latin America paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 60 Brazil country dynamics
  • Fig. 61 Brazil paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 62 Argentina country dynamics
  • Fig. 63 Argentina paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 64 MEA paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 65 South Africa country dynamics
  • Fig. 66 South Africa paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 67 Saudi Arabia country dynamics
  • Fig. 68 Saudi Arabia paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 69 UAE country dynamics
  • Fig. 70 UAE paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 71 Kuwait country dynamics
  • Fig. 72 Kuwait paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 73 Company categorization
  • Fig. 74 Company market position analysis
  • Fig. 75 Strategic framework
目次
Product Code: GVR-2-68038-622-6

Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth & Trends:

The global paroxysmal nocturnal hemoglobinuria (PNH) treatment market size is expected to reach USD 9.96 billion by 2030, registering a CAGR of 9.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. Several factors such as rise in the number of blood and bone marrow related disorders, an increase in the geriatric population, wider adoption of novel therapeutics, and the emergence of biologics are driving the market.

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, chronic hematologic disorder. It is an ultra-rare disease with approximately 8,000 to 10,000 cases reported in North America and Europe. The life-threatening disease often manifests in three forms: thrombosis, persistent intravascular hemolysis, and pancytopenia. Although the information on its prevalence is scarce, PNH is estimated to affect more than 20,000 people worldwide with an incidence of about 1.3 per million annually and a prevalence of around 16 per million. PNH affects men and women equally. Although physical symptoms can begin at any age, they usually develop between 30-40 years of age.

Novel treatments including monoclonal antibodies, recombinant proteins, and cyclic peptides are gaining penetration in developed markets. However, the high cost of therapy with Soliris and other emerging pipeline drugs presents a barrier in adoption in developing regions. Blood transfusion and supportive care are anticipated to lose momentum during the forecast period due to adverse side effects and suboptimal efficacy.

Paroxysmal Nocturnal Hemoglobinuria Treatment Market Report Highlights:

  • An estimated 5,000 - 6,000 people in the U.S. suffer from PNH, with approximately 450 new cases being reported annually
  • U.S. dominated the global PNH treatment market dominated with a significant revenue share in 2024 due to the high cost of treatment in the U.S., potential approval of a range of pipeline drugs, and adoption of novel therapeutics
  • Treatment with medication dominated the PNH market with a share of more than 85.3% in 2024. Apart from drugs, the stem cell transplant segment is projected to witness double-digit growth through the forecast period
  • Currently, 16 products are under clinical evaluation for PNH treatment in various stages of development. Promising pipeline candidates such as ALXN1210, Coversin, APL2, and RA101495 offer significant commercial potential post regulatory approval.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Paroxysmal Nocturnal Hemoglobinuria Treatment Market: Treatment Business Analysis

  • 4.1. Treatment Market Share, 2024 & 2030
  • 4.2. Treatment Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Billion)
  • 4.4. Medication
    • 4.4.1. Medication Market, 2018 - 2030 (USD Billion)
  • 4.5. Stem Cell Transplant
    • 4.5.1. Stem Cell Transplant Market, 2018 - 2030 (USD Billion)
  • 4.6. Blood Transfusion
    • 4.6.1. Blood Transfusion Market, 2018 - 2030 (USD Billion)
  • 4.7. Other Treatment Types
    • 4.7.1. Other Treatment Types Market, 2018 - 2030 (USD Billion)

Chapter 5. Paroxysmal Nocturnal Hemoglobinuria Treatment Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Market Share Analysis, 2024 & 2030
  • 5.2. Regional Market Dashboard
  • 5.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 5.4. North America
    • 5.4.1. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 5.4.2. U.S.
      • 5.4.2.1. Key Country Dynamics
      • 5.4.2.2. Regulatory Framework
      • 5.4.2.3. Competitive Insights
      • 5.4.2.4. U.S. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.4.3. Canada
      • 5.4.3.1. Key Country Dynamics
      • 5.4.3.2. Regulatory Framework
      • 5.4.3.3. Competitive Insights
      • 5.4.3.4. Canada Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.4.4. Mexico
      • 5.4.4.1. Key Country Dynamics
      • 5.4.4.2. Regulatory Framework
      • 5.4.4.3. Competitive Insights
      • 5.4.4.4. Mexico Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5. Europe
    • 5.5.1. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 5.5.2. UK
      • 5.5.2.1. Key Country Dynamics
      • 5.5.2.2. Regulatory Framework
      • 5.5.2.3. Competitive Insights
      • 5.5.2.4. UK Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.5.3. Germany
      • 5.5.3.1. Key Country Dynamics
      • 5.5.3.2. Regulatory Framework
      • 5.5.3.3. Competitive Insights
      • 5.5.3.4. Germany Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.5.4. France
      • 5.5.4.1. Key Country Dynamics
      • 5.5.4.2. Regulatory Framework
      • 5.5.4.3. Competitive Insights
      • 5.5.4.4. France Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.5.5. Italy
      • 5.5.5.1. Key Country Dynamics
      • 5.5.5.2. Regulatory Framework
      • 5.5.5.3. Competitive Insights
      • 5.5.5.4. Italy Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.5.6. Spain
      • 5.5.6.1. Key Country Dynamics
      • 5.5.6.2. Regulatory Framework
      • 5.5.6.3. Competitive Insights
      • 5.5.6.4. Spain Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.5.7. Norway
      • 5.5.7.1. Key Country Dynamics
      • 5.5.7.2. Regulatory Framework
      • 5.5.7.3. Competitive Insights
      • 5.5.7.4. Norway Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.5.8. Denmark
      • 5.5.8.1. Key Country Dynamics
      • 5.5.8.2. Regulatory Framework
      • 5.5.8.3. Competitive Insights
      • 5.5.8.4. Denmark Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.5.9. Sweden
      • 5.5.9.1. Key Country Dynamics
      • 5.5.9.2. Regulatory Framework
      • 5.5.9.3. Competitive Insights
      • 5.5.9.4. Sweden Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 5.6. Asia Pacific
    • 5.6.1. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.6.2. Japan
      • 5.6.2.1. Key Country Dynamics
      • 5.6.2.2. Regulatory Framework
      • 5.6.2.3. Competitive Insights
      • 5.6.2.4. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.6.3. China
      • 5.6.3.1. Key Country Dynamics
      • 5.6.3.2. Regulatory Framework
      • 5.6.3.3. Competitive Insights
      • 5.6.3.4. China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.6.4. India
      • 5.6.4.1. Key Country Dynamics
      • 5.6.4.2. Regulatory Framework
      • 5.6.4.3. Competitive Insights
      • 5.6.4.4. India Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.6.5. South Korea
      • 5.6.5.1. Key Country Dynamics
      • 5.6.5.2. Regulatory Framework
      • 5.6.5.3. Competitive Insights
      • 5.6.5.4. South Korea Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.6.6. Australia
      • 5.6.6.1. Key Country Dynamics
      • 5.6.6.2. Regulatory Framework
      • 5.6.6.3. Competitive Insights
      • 5.6.6.4. Australia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.6.7. Thailand
      • 5.6.7.1. Key Country Dynamics
      • 5.6.7.2. Regulatory Framework
      • 5.6.7.3. Competitive Insights
      • 5.6.7.4. Thailand Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.7. Latin America
    • 5.7.1. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 5.7.2. Brazil
      • 5.7.2.1. Key Country Dynamics
      • 5.7.2.2. Regulatory Framework
      • 5.7.2.3. Competitive Insights
      • 5.7.2.4. Brazil Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.7.3. Argentina
      • 5.7.3.1. Key Country Dynamics
      • 5.7.3.2. Regulatory Framework
      • 5.7.3.3. Competitive Insights
      • 5.7.3.4. Argentina Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.8. MEA
    • 5.8.1. MEA Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 5.8.2. South Africa
      • 5.8.2.1. Key Country Dynamics
      • 5.8.2.2. Regulatory Framework
      • 5.8.2.3. Competitive Insights
      • 5.8.2.4. South Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.8.3. Saudi Arabia
      • 5.8.3.1. Key Country Dynamics
      • 5.8.3.2. Regulatory Framework
      • 5.8.3.3. Competitive Insights
      • 5.8.3.4. Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.8.4. UAE
      • 5.8.4.1. Key Country Dynamics
      • 5.8.4.2. Regulatory Framework
      • 5.8.4.3. Competitive Insights
      • 5.8.4.4. UAE Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.8.5. Kuwait
      • 5.8.5.1. Key Country Dynamics
      • 5.8.5.2. Regulatory Framework
      • 5.8.5.3. Competitive Insights
      • 5.8.5.4. Kuwait Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Competitive Landscape

  • 6.1. Participant Overview
  • 6.2. Company Market Position Analysis
  • 6.3. Company Categorization
  • 6.4. Strategy Mapping
  • 6.5. Company Profiles/Listing
    • 6.5.1. Alexion Pharmaceuticals, Inc.
      • 6.5.1.1. Overview
      • 6.5.1.2. Financial Performance
      • 6.5.1.3. Treatment Benchmarking
      • 6.5.1.4. Strategic Initiatives
    • 6.5.2. Apellis Pharmaceuticals
      • 6.5.2.1. Overview
      • 6.5.2.2. Financial Performance
      • 6.5.2.3. Treatment Benchmarking
      • 6.5.2.4. Strategic Initiatives
    • 6.5.3. Novartis AG
      • 6.5.3.1. Overview
      • 6.5.3.2. Financial Performance
      • 6.5.3.3. Treatment Benchmarking
      • 6.5.3.4. Strategic Initiatives
    • 6.5.4. F. Hoffmann-La Roche Ltd
      • 6.5.4.1. Overview
      • 6.5.4.2. Financial Performance
      • 6.5.4.3. Treatment Benchmarking
      • 6.5.4.4. Strategic Initiatives
    • 6.5.5. Genentech, Inc.
      • 6.5.5.1. Overview
      • 6.5.5.2. Financial Performance
      • 6.5.5.3. Treatment Benchmarking
      • 6.5.5.4. Strategic Initiatives
    • 6.5.6. BioCryst Pharmaceuticals, Inc.
      • 6.5.6.1. Overview
      • 6.5.6.2. Financial Performance
      • 6.5.6.3. Treatment Benchmarking
      • 6.5.6.4. Strategic Initiatives
    • 6.5.7. Regeneron Pharmaceuticals Inc.
      • 6.5.7.1. Overview
      • 6.5.7.2. Financial Performance
      • 6.5.7.3. Treatment Benchmarking
      • 6.5.7.4. Strategic Initiatives
    • 6.5.8. Sanofi
      • 6.5.8.1. Overview
      • 6.5.8.2. Financial Performance
      • 6.5.8.3. Treatment Benchmarking
      • 6.5.8.4. Strategic Initiatives
    • 6.5.9. Pfizer Inc.
      • 6.5.9.1. Overview
      • 6.5.9.2. Financial Performance
      • 6.5.9.3. Treatment Benchmarking
      • 6.5.9.4. Strategic Initiatives
    • 6.5.10. Amgen Inc.
      • 6.5.10.1. Overview
      • 6.5.10.2. Financial Performance
      • 6.5.10.3. Treatment Benchmarking
      • 6.5.10.4. Strategic Initiatives